Evidence map›Paper›PMID 40539828›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Lysosomal Cathepsin S Escape Facilitates Near Infrared Light-Triggered Pyroptosis Via an Antibody-Indocyanine Green Conjugate.

Fan Chen, Xue-Fei Tian, Teng Yang, Yu-Jie Dai, Da-Yuan Chen, Hong-Bo Chen, Takaya Shimura, Xin-Fang Li, Chu-Lin Sha, Qing Ji and 8 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Fan ChenZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.ORCID https://orcid.org/0009-0001-1129-8856
Xue-Fei TianZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Teng YangZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Yu-Jie DaiMabPlex International, Yantai, Shandong, 264006, China.
Da-Yuan ChenGuilin University of Electronic Technology, Guilin, Guangxi, 541004, China.
Hong-Bo ChenGuilin University of Electronic Technology, Guilin, Guangxi, 541004, China.
Takaya ShimuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan.
Xin-Fang LiMabPlex International, Yantai, Shandong, 264006, China.
Chu-Lin ShaZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Qing JiDepartment of Head and Neck and Rare Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China.
Jun CaoDepartment of Head and Neck and Rare Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China.
Mei-Yu FangDepartment of Head and Neck and Rare Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China.
Jin-Biao ShangZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Jian-Min FangSchool of Life Science and Technology, Tongji University, Shanghai, 200092, China.
Ye LuZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Wei-Hui ZhengZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.
Peng GuoZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.ORCID https://orcid.org/0009-0004-8215-7673
Wei-Hong TanZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China.

Funding

National Key Research and Development Program 2023YFC3404003National Natural Science Foundation of China 82172598National Natural Science Foundation of China 82202231National Natural Science Foundation of China 82373782National Natural Science Foundation of China 92353000National Natural Science Foundation of China T2188102Natural Science Foundation of Zhejiang Province, China LZ22H310001the 551 Health Talent Training Project of Health Commission of Zhejiang Provincethe Joint Research Program of Eye Research Center ERC2024014the Key Research and Development Program of Zhejiang Province 2024SDYXS0001the Qiantang Interdisciplinary Research Grantthe Research Funds of Hangzhou Institute for Advanced Study 2024HIAS-V008
6 · The paper itself

Abstract

Pyroptosis is a proinflammatory programmed cell death (PCD) that is causally linked to antitumor immune responses, but the therapeutic potential of pyroptosis has been limited by the lack of tumor-specific and controllable inducers. Here, it is reported that tumor-specific pyroptosis can be spatiotemporally triggered via near-infrared light (NIR-pyroptosis) by using an antibody-bound indocyanine green (ICG), a clinically approved and nontoxic fluorescent dye. Mechanistically, the key molecular steps are identified by which antibody-bound ICG generates excessive reactive oxygen species (ROS) within lysosomes after internalization, leading to lysosomal membrane damage and the cytosolic release of cathepsin S (CTSS), which cleaves gasdermin D (GSDMD), IL-18, and IL-1β independently of caspase-1, and thereby induces pyroptosis, while other cathepsin family members fail to cleave GSDMD. Functionally, in both ICAM1+ and HER2+ solid tumors, antibody-bound ICG-mediated NIR-pyroptosis triggers potent and durable antitumor immune responses through the release of proinflammatory cytokines. Furthermore, NIR-pyroptosis synergize with anti-PD-1 therapy by activating adaptive immune cells via upregulated IFN-γ secretion. The findings identify CTSS as a novel enzyme for GSDMD cleavage and establish NIR-pyroptosis as a non-apoptotic anticancer modality, providing a promising opportunity to overcome apoptosis resistance in current cancer therapies.

Indexed as

CathepsinsIndocyanine GreenLysosomesPyroptosisAnimalsCell Line, TumorHumansInfrared RaysInterleukin-18MicePhosphate-Binding ProteinsReactive Oxygen Speciescathepsin SCathepsinsIndocyanine GreenInterleukin-18Phosphate-Binding ProteinsReactive Oxygen Speciesantibody‐drug conjugateanti‐tumor immunitypyroptosis

Identifiers

PMID40539828
PMCPMC12442674

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.